HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2022 at "Theranostics"
DOI: 10.7150/thno.69444
Abstract: Rationale: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a dismal 5-year survival less than 10%. Most patients with PDAC exhibit poor response to single-agent immunotherapy. Multimodal therapies targeting mechanisms of resistance to immunotherapy… read more here.
Keywords: cancer; hdac5; immunity; modulates expression ... See more keywords